New Insights from the Phase III MARIPOSA Trial on Amivantamab and Lazertinib Combination for NSCLC Patients The MARIPOSA trial reveals promising results for the combination therapy of Amivantamab and Lazertinib in Asian NSCLC patients, indicating improved survival rates compared to single-agent therapy.

New Insights from the Phase III MARIPOSA Trial on Amivantamab and Lazertinib Combination for NSCLC Patients #Japan #Tokyo #NSCLC #Lazertinib #Amivantamab

Lasering in on Uncommon EGFR Mutations

An editorial from Drs. So Yeon Kim, Katerina Politi, and
Sarah Goldberg emphasizes the promising activity and safety of #lazertinib in #NSCLC with uncommon EGFR mutations, supporting further study.
sciencedirect.com/science/arti...
@yalepathology.bsky.social

Actualmente, existen 3 opciones de tratamiento de primera línea para mutaciones EGFR:

- #Osimertinib
- #Osimertinib + #Quimioterapia
- #Amivantamab + #Lazertinib

Si quieres saber más sobre estos tratamientos, únete al evento con la Dra. Ana Velázquez Mañana, MD MSc FASCO (Velazquez Manana)

Breaking New Ground: Lazertinib and Amivantamab Boost Survival in EGFR-Mutant NSCLC Patients A groundbreaking combination therapy of Lazertinib and Amivantamab demonstrates significant survival benefits for patients with EGFR-mutant non-small cell lung cancer in recent clinical trials.

Breaking New Ground: Lazertinib and Amivantamab Boost Survival in EGFR-Mutant NSCLC Patients #Japan #Tokyo #NSCLC #Lazertinib #Amivantamab

Amivantamab plus lazertinib shows survival benefit in lung cancer - PharmaTimes Janssen drug combination extends life expectancy during trial

#oncology #Amivantamab #lazertinib #lungcancer #Janssen #phase3clinicaltrial #MARIPOSAstudy #EGFRmutatedadvancednonsmallcelllungcancer #NSCLC #nonsmallcelllungcancer #Rybrevant #Lazcluze #EuropeanLungCancerCongress #lungcancertreatment #patientoutcomes
pharmatimes.com/news/amivant...

COCOON study meets primary endpoint demonstrating statistically significant and clinically meaningful reduction in dermatologic reactions with easy-to-use prophylactic regimen for patients with EGFR-m...

How to reduce skin toxicity from #amivantamab #lazertinib in #NSCLC?
📝 oral antibiotic (doxycycline or minocycline) twice daily for 12 weeks 💊, then topical antibiotic (clindamycin 1 percent), antibacterial wash (chlorhexidine 4 percent), and daily ceramides-based noncomedogenic moisturizer 🧴

EC approves Rybrevant with Lazcluze for advanced lung cancer - PharmaTimes New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC

#Rybrevant #amivantamab #Lazcluze #lazertinib #advancedlungcancer #lungcancer #EGFRmutatedNSCLC #JanssenCilagInternational #advancednonsmallcelllungcancer #NSCLC #nonsmallcelllungcancer #thoraciccancer #EGFRmutationpositiveNSCLC #precisionmedicine #MARIPOSAstudy
pharmatimes.com/news/europea...